Literature DB >> 6666557

Deep vein thrombosis during pregnancy. A prospective study.

A Bergqvist, D Bergqvist, T Hallböök.   

Abstract

Seventeen women with thrombosis during pregnancy were studied prospectively. The deep venous thrombosis (DVT) was diagnosed objectively with phlebography, plethysmography and thermography. In many cases (13/17) the dominant symptom was diffuse pain in the lower abdomen and/or leg which in several cases caused a delay in the diagnosis. The traditionally typical thrombotic signs were often missing. Proximal thrombi were predominant (13/17) as were left-sided ones (14/17). During pregnancy and lactation the patients were treated with heparin which, after the initial parenteral administration, was given subcutaneously by self-administration. In conclusion, DVT must be suspected and non-invasive diagnostic tests be liberally performed in cases of uncharacteristic lateral and/or declive abdominal pain or leg pain during pregnancy. The DVT must always be objectively verified before treatment. In patients with pregnancy DVT there is no indication for early labor induction and the patients can be delivered by the normal vaginal route. It is recommended that patients with DVT during pregnancy should be treated with heparin subcutaneously which can be self-administered. The post-partum treatment may be continued for 2-3 months with heparin subcutaneously or peroral anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6666557     DOI: 10.3109/00016348309154217

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  2 in total

Review 1.  Anatomic distribution of deep vein thrombosis in pregnancy.

Authors:  Wee-Shian Chan; Frederick A Spencer; Jeffrey S Ginsberg
Journal:  CMAJ       Date:  2010-03-29       Impact factor: 8.262

Review 2.  Emerging concepts in the diagnosis and management of venous thromboembolism during pregnancy.

Authors:  M M Burns
Journal:  J Thromb Thrombolysis       Date:  2000-08       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.